Slide 1: Report Q1 2025
Report Q1 2025 May 7, 2025 Cecilia de Leeuw Linda Frölén CEO CFO
Slide 2: Progress on our strategy in Q1
Progress on our strategy in Q1 Grow Sales & World-leading Untapped Market Financial Stability & Market Reach Globally Products Potential Profitable Growth Revenue and operating income 2022-2025(RTM), MSEK • Strengthen position by • Patient-centric and user- • SGRT (Surface Guided 600 80 growing in p
Slide 3: Solid quarter in wait-and-see market
Solid quarter in wait-and-see market Order Intake YoY: Order intake 97 MSEK, with growth in EMEA & APAC 5% Revenue YoY: Revenue 119 MSEK, Americas and APAC key drivers 1% EBIT margin: Solid adjusted EBIT margin, due to cost-efficiency 18%* * Excluding unrealized currency effects
Slide 4: Q1 development by region
Q1 development by region Order Intake (MSEK) Q1’25 Q1’24 % AMERICAS – Revenue Growth and backlog conversion Americas 19 25 -21% Progress on Varian focus with retrofit orders EMEA 38 33 +15% Proton position confirmed by Wisconsin contract APAC 40 34 +15% EMEA – Proactivity paying off Growing footprin
Slide 5: Successful ESTRO 2025 trade show
Successful ESTRO 2025 trade show Record number of visitors from all over the world and highly qualified discussions Live demos to show-case our technology to customers and prospects Launched new product enhancements and Catalyst+LITE Advancing safer, more precise, and personalized cancer care throug
Slide 6: Q1 Financials
Q1 Financials Linda Frölén, CFO
Slide 7: Q1 Financials
Q1 Financials Order Intake Revenue Gross Profit Gross Margin 96.5 (91.6) MSEK 118.8 (118.0) MSEK 78.0 (76.6) MSEK 66 (65) % +5% +1% +1% +74 bips EBIT 10.0 (14.2) MSEK EBIT Margin OPEX -29% 9 (12) % Operating Cash Flow 56.1 (64.0) MSEK Adj for unrealized fx Adj for unrealized fx 25.7 (16.5) MSEK -12%
Slide 8: Stable Gross Margin in the mid-60s
Stable Gross Margin in the mid-60s Gross profit & Gross margin by month Gross profit Q1’25: 100,0 74% 78.0 (76.6) MSEK 90,0 72% Increase Y/Y following higher revenue coupled 80,0 by positive mix effects 70% 70,0 68% 60,0 Gross margin Q1’25: 50,0 66% 66 (65) % 40,0 64% Gross margin in line with both
Slide 9: Other operating expenses & personell
Other operating expenses & personell Development Y/Y: -7.9 MSEK 70,0 Lower expenses for legal fees, 64,0 Y/Y Q/Q other external expenses and 60,0 56,1 57,1 56,1 external consultants 50,0 Development Q/Q: -1.0 MSEK 40,0 Lower expenses for travelling 30,0 20,0 10,0 0,0 Q1'24 Q1'25 Q4'24 Q1'25
Slide 10: Solid underlying operating margin
Solid underlying operating margin EBIT Q1’25: 90,0 Rolling 12 months 18% 10.0 (14.2) MSEK 80,0 16% Adjusted for unrealized fx 70,0 14% 21.2 (11.9) MSEK 60,0 12% 50,0 10% 40,0 8% EBIT margin Q1’25: 30,0 6% 9 (12) % 20,0 4% Adjusted for unrealized fx 10,0 2% 18 (10) % 0,0 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23
Slide 11: Continued positive cash flow and strong balance sheet
Continued positive cash flow and strong balance sheet Total cash flow by quarter (MSEK) Cash balance increased with 10 MSEK from 151 60,0 MSEK at year-end to 161 MSEK at quarter end 40,0 Operating cash flow of 26 MSEK whereof 16 MSEK from working capital improvements. 20,0 Main contributor to cash f
Slide 12: Looking ahead
Looking ahead Cecilia de Leeuw, CEO
Slide 13: C-RAD communicates medium-term financial targets
C-RAD communicates medium-term financial targets Average organic growth to exceed 10% Operating margin (EBIT margin) to reach 25% At least 30% of net profit to be returned to shareholders When determining dividends, investment needs and other strategic factors that the board deems to be important wi
Slide 14: C-RAD strategy and main priorities
C-RAD strategy and main priorities Increase sales by gaining market share and growing our offering Invest in product innovation through product development of the existing portfolio and launching new complementary solutions Develop and grow the service offering Build a resilient business to grow pro
Slide 15: Q&A
Q&A Cecilia de Leeuw Linda Frölén CEO CFO
Slide 16: Slide 16